000000_Synthonics_ChyloCureBook_Rev031919

Company will give the Investor the opportunity to invest the Note Value (as defined above) in the Qualified Financing All investors receiving Qualified Securities or common stock will be required, as a condition to the issuance of the Qualified Securities or common stock, to execute and join the Company’s Stockholders’ Agreement. All purchases of Notes shall be made pursuant to the Company’s Note Purchase Agreement.

Agreements:

KEY EXECUTIVES AND ADVISORS • Tom Piccariello. CEO. Dr. Piccariello is a founder and the president and chief science officer of Synthonics. He was the lead inventor of the Carrierwave technology (attaching a peptide to an active agent to make that agent less subject to abuse) that ultimately led to the discovery, development and launch of Vyvanse (lisdexamfetamine dimesylate for treatment of ADHD) at New River Pharmaceuticals. Shortly after the commercial launch of Vyvanse, Shire acquired New River for approximately $2.4 billion. Dr. Piccariello has experience in the fields of synthetic chemistry, metallurgy, electrochemistry, plant enzymology, chemical manufacturing and pharmacology. In addition to serving as the lead scientist for two pharmaceutical start-up companies (both of which became public), Dr. Piccariello founded and ran contract research and contract manufacturing companies, which he later sold. Dr. Piccariello has 23 patents and patent applications to his credit, 18 of which deal with novel drug delivery technologies. He has a B.S. in biology and a Ph.D. in chemistry from Virginia Polytechnic Institute and State University (Virginia Tech). • Ken Slepicka. Director/President of Mid-West Operations and National Sales. Mr. Slepicka is a founder and former chief executive officer of Synthonics. He has been actively involved in the medical cannabis space since 2014 and has helped develop and refine our cannabinoid purification process. He has deep knowledge of the medical cannabis industry and has developed connections with many leading cannabis distributors and retailers. He is expert in in the formulation of cannabinoid containing products. • Scott Palmer. Dr. Scott Palmer, M.D., is a board-certified physician in Internal Medicine. He is a graduate of the University of Michigan and Rush Medical College. Dr. Palmer did his internship, residency and chief residency at Presbyterian St. Luke's Hospital in Chicago, Illinois. Dr. Palmer has been selected as one of the "Top Doctors: Chicago Metro Area" by Castle Connolly Medical Ltd. and Consumer's Checkbook, as well as being selected "America's Top Physicians" by Consumer's Research Council of America, Washington, D.C. Dr. Palmer is a member of the American Medical Association, American College of Physicians and the Chicago Society of Medical Medicine. Dr. Palmer is also the Medical Team Physician of the Chicago Bulls and the Chicago White Sox. In addition to chairing Synthonics Inc. Scientific Advisory Board, Dr. Palmer is a member of Synthonics Board of Directors. Dr. Palmer's interests are in pharmaceutical research, exploring the treatment of autism, cancer, neurodegenerative disorders and infectious diseases.

8